Ishii Tomomi

Dr. Ishii Tomomi

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Genes
Verified
Journal Article
Open access
PDF file
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
KMKeiko Mukaida
Keiko Mukaida
SOSachiko Otsuki
Sachiko Otsuki
KKKenshiro Kido
Kenshiro Kido
ASAyako Sumii
Ayako Sumii
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Background: Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle triggered by certain anesthetic agents. While Ryanodine Receptor 1 (RYR1) and Calcium Voltage-Gated Channel Subunit Alpha1 S (CACNA1S) are well-established susceptibility genes, the complete genetic basis of MH remains unclear, particularly in Asian populations. Methods: We conducted gene panel testing targeting 24 calcium-related genes in 338 individuals from 247 Japanese families with suspected or confirmed MH. Variants were analyzed on a gene-by-gene basis, and their pathogenicity was assessed using in silico prediction tools. Additionally, patients were classified into subgroups based on the results of the calcium-induced calcium release (CICR) assay and the Clinical Grading Scale (CGS) score. Results: Candidate pathogenic variants were identified in 118 families (48.2%), including 73 (29.8%) in RYR1, 16 (6.5%) in CACNA1S, and 62 (25.3%) in other genes. Among CICR-positive families, RYR1 and CACNA1S variants were detected in 42.0% and 5.3% of cases, respectively. In individuals with high CGS scores (Ranks 5–6), RYR1 and CACNA1S variants were observed in 56.0% and 12.0%, respectively. Variants in other genes such as STAC3, CASQ1, ATP2A1, ASPH, HRC and TRPV1 were also detected. Conclusions: Our findings confirm the predominant role of RYR1 and CACNA1S in MH susceptibility in the Japanese population and highlight additional candidate genes that may contribute to the condition. Broader genetic screening and functional validation studies are warranted to further elucidate the polygenic nature of MH.

4 October 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ITIshii Tomomi
Ishii Tomomi
TKTaketoshi Kajimoto
Taketoshi Kajimoto
SKSatoshi Kikkawa
Satoshi Kikkawa
SNSoshi Narasaki
Soshi Narasaki
SNSoma Noguchi
Soma Noguchi
NSNorio Sakai
Norio Sakai

9 November 2023 in A&A Practice
Verified
Journal Article
Closed access
ITIshii Tomomi
Ishii Tomomi
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
TKTakashi Kubo
Takashi Kubo
YTYasuo M. Tsutsumi
Yasuo M. Tsutsumi
YHYousuke T. Horikawa
Yousuke T. Horikawa
HTHiroyuki Tanaka
Hiroyuki Tanaka
Ropivacaine is an amide local anesthetic with rare reports of anaphylaxis. To our knowledge, this is the first report of delayed nonimmune anaphylaxis induced by ropivacaine. A 70-year-old man underwent general anesthesia with a nerve block for a total knee arthroplasty. The patient developed symptoms of anaphylaxis 3.5 hours after receiving ropivacaine for femoral and tibial nerve blocks. A basophil activation test (BAT) revealed ropivacaine as the causative agent. Notably, anaphylaxis can be caused by medications even hours after their administration, and all administered drugs should be suspected of potentially causing anaphylaxis.

22 July 2025 in Anaesthesia Reports
Verified
Journal Article
Open access
ITIshii Tomomi
Ishii Tomomi
HMH. Miyoshi
H. Miyoshi
HSH. Sato
H. Sato
HYH. Yokomi
H. Yokomi
TTT. Takasaki
T. Takasaki
YTY. M. Tsutsumi
Y. M. Tsutsumi

23 July 2026 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
GXGuo-Qiang Xia
Guo-Qiang Xia
SOSachiko Otsuki
Sachiko Otsuki
KMKeiko Mukaida
Keiko Mukaida
MXMiao Xu
Miao Xu
KKKenshiro Kido
Kenshiro Kido
HMHirotsugu Miyoshi
Hirotsugu Miyoshi

20 August 2026 in Genes
Verified
Journal Article
Open access
PDF file
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
SOSachiko Otsuki
Sachiko Otsuki
KKKenshiro Kido
Kenshiro Kido
ASAyako Sumii
Ayako Sumii
TITsuyoshi Ikeda
Tsuyoshi Ikeda
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Background/Objectives: Malignant hyperthermia (MH) is a life-threatening pharmacogenetic disorder of skeletal muscle primarily associated with pathogenic variants in RYR1; however, a substantial proportion of MH-susceptible individuals lack identifiable variants in known genes. This study aimed to identify novel genetic contributors in Ca2+-induced Ca2+ release (CICR)-positive patients without RYR1 variants and to evaluate their functional relevance. Methods: Among 29 CICR-positive individuals without pathogenic variants identified by gene panel testing, five patients underwent whole-exome sequencing (WES). In one family, heterozygous variants in ANO5 (p.Arg547Gln) and ORAI3 (p.Arg287Cys) were identified. To evaluate their functional significance, intracellular Ca2+ dynamics were analyzed in primary myotubes derived from Case 165, an affected individual carrying both variants, and compared with those from CICR-negative controls and CICR-positive patients harboring RYR1 variants. Results: Myotubes derived from Case 165 demonstrated enhanced sensitivity to caffeine and 4-chloro-m-cresol, elevated resting intracellular Ca2+ levels, and greater Ca2+ reduction under Ca2+-free conditions compared with CICR-negative controls, resembling the phenotype observed in the RYR1 variant group. In contrast, dantrolene-induced Ca2+ reduction was significantly greater only in the RYR1 variant group. Conclusions: These findings suggest that ANO5 and ORAI3 variants may contribute to abnormal Ca2+ regulation in MH-susceptible individuals without RYR1 mutations and highlight the importance of combining genomic analysis with functional validation to identify novel genetic contributors to MH susceptibility.